title: HIV-related lymphoma treated with maintenance thalidomide.
authors.affiliation: Rush University Medical Center, Chicago, IL 60612, USA. Melissa_L_Larson@rush.edu
authors.forename: Melissa L
authors.initials: ML
authors.lastname: Larson
authors.forename: Sari H
authors.initials: SH
authors.lastname: Enschede
authors.forename: Stephanie A
authors.initials: SA
authors.lastname: Gregory
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D001365:Axilla; D016190:Carboplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007167:Immunotherapy; D015182:Lymphatic Irradiation; D016483:Lymphoma, AIDS-Related / Q000188:drug therapy* / Q000532:radiotherapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000532:radiotherapy; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D000069283:Rituximab; D013792:Thalidomide / Q000627:therapeutic use*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D013792:Thalidomide; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D016190:Carboplatin; D007069:Ifosfamide; D011241:Prednisone